MYNZ Stock Overview
Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Mainz Biomed N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.90 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$0.85 |
| Beta | 0.24 |
| 1 Month Change | -12.23% |
| 3 Month Change | -16.30% |
| 1 Year Change | -79.45% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.95% |
Recent News & Updates
Shareholder Returns
| MYNZ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.0% | -4.7% | -3.7% |
| 1Y | -79.5% | -2.7% | 20.2% |
Return vs Industry: MYNZ underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: MYNZ underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| MYNZ volatility | |
|---|---|
| MYNZ Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MYNZ's share price has been volatile over the past 3 months.
Volatility Over Time: MYNZ's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 68 | Guido Baechler | mainzbiomed.com |
Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases.
Mainz Biomed N.V. Fundamentals Summary
| MYNZ fundamental statistics | |
|---|---|
| Market cap | US$19.79m |
| Earnings (TTM) | -US$26.30m |
| Revenue (TTM) | US$895.48k |
22.1x
P/S Ratio-0.8x
P/E RatioIs MYNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYNZ income statement (TTM) | |
|---|---|
| Revenue | US$895.48k |
| Cost of Revenue | US$385.82k |
| Gross Profit | US$509.66k |
| Other Expenses | US$26.81m |
| Earnings | -US$26.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 56.91% |
| Net Profit Margin | -2,936.50% |
| Debt/Equity Ratio | 183.6% |
How did MYNZ perform over the long term?
See historical performance and comparison